Organon & Co.
NYSE:OGNDrug Manufacturers - General
+$0.01 today
- Market cap
- $3.66B
- Beta
- 1.54
- P/E (TTM)
- 14.2
- EPS (TTM)
- $0.94
- Dividend yield
- 0.60%
Volume 3.90M
Average 8.57M
OGN Total Current Assets
All assets expected to be converted to cash or used up within one year.
Organon & Co.NYSE: OGN
Total Current Assets · Q3 FY2026 · quarter ended Sep 2026
Total current assets rises 14.2% from a year ago
Total current assets stood at $5.37B at the end of Q3 FY2026, up 14.2% from a year earlier and up 5.0% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.
Context
- Total current assets amounted to 40.1% of total assets at the end of Q3 FY2026, up 5.4 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +14.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 4.35B USD
- Year-over-year change
- +0.1%
- 4-year CAGR
- +3.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.35B | +0.1% |
| FY2024 | 2024-12-31 | 4.35B | -3.5% |
| FY2023 | 2023-12-31 | 4.51B | +14.7% |
| FY2022 | 2022-12-31 | 3.93B | +4.5% |
| FY2021 | 2021-12-31 | 3.76B | — |
Total Current Assets vs competitors
How OGN compares with its peers on the latest reported figures
- OGN's Sep 2026 total current assets of $5.37B is the highest of the 10 companies compared; the peer median is $718.76M.
- Its year-over-year change of +14.2% is the 6th highest of 10, against a peer median of +15.2%.
- Total current assets amounts to 40.1% of total assets for OGN, versus a peer median of 57.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $5.37B | +14.2% | +3.4% | 40.1% | |
| Mar 2026 | $1.11B | +1.8% | -6.9% | 18.4% | |
| Mar 2026 | $894.07M | +15.2% | +12.7% | 61.9% | |
| Jun 2026 | $814.33M | +17.8% | +31.3% | 59.3% | |
| Jun 2026 | $726.43M | +16.6% | -5.0% | 97.6% | |
| Feb 2026 | $718.76M | -27.5% | -2.3% | 34.6% | |
| Sep 2026 | $684.08M | -4.6% | +21.3% | 32.0% | |
| Jun 2026 | $541.32M | +32.4% | +3.6% | 68.3% | |
| Mar 2026 | $455.98M | -0.6% | +35.5% | 32.1% | |
GRDNGuardian Pharmacy Services, Inc. | Jun 2026 | $254.67M | +49.4% | +22.7% | 57.4% |
| Peer median (excluding OGN) | $718.76M | +15.2% | +12.7% | 57.4% | |
Competitors are the stored peer set for OGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 737M | 706M | 693M | 675M | 574M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.51B | 1.61B | 1.86B | 1.49B | 1.43B |
| Inventory | 915M | 1B | 1.32B | 1.32B | 1.41B |
| Other Current Assets | 596M | 616M | 643M | 861M | 939M |
| Total Current Assets | 3.76B | 3.93B | 4.51B | 4.35B | 4.35B |
| Property, Plant & Equipment (Net) | 1.2B | 1.23B | 1.36B | 1.33B | 1.3B |
| Goodwill | 4.6B | 4.6B | 4.6B | 4.68B | 4.15B |
| Intangible Assets | 651M | 649M | 533M | 1.41B | 1.13B |
| Long-term Investments | 0 | 0 | 0 | 27M | 0 |
| Tax Assets | 0 | 267M | 808M | 946M | 0 |
| Other Non-current Assets | 464M | 272M | 250M | 361M | 1.93B |
| Total Non-current Assets | 6.92B | 7.02B | 7.55B | 8.75B | 8.52B |
| Total Assets | 10.68B | 10.96B | 12.06B | 13.1B | 12.87B |
| Account Payables | 1.38B | 1.13B | 1.31B | 1.15B | 952M |
| Short-term Debt | 55M | 57M | 55M | 64M | 56M |
| Tax Payables | 185M | 184M | 206M | 134M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 975M | 1.14B | 1.34B | 1.37B | 1.3B |
| Total Current Liabilities | 2.6B | 2.51B | 2.92B | 2.72B | 2.39B |
| Long-term Debt | 9.13B | 8.91B | 8.75B | 8.86B | 8.64B |
| Deferred Tax Liabilities | 4M | 19M | 47M | 74M | 57M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 279M | 261M | 287M | 865M | 924M |
| Total Non-current Liabilities | 9.59B | 9.34B | 9.21B | 9.91B | 9.73B |
| Total Liabilities | 12.19B | 11.85B | 12.13B | 12.63B | 12.12B |
| Common Stock | 3M | 3M | 3M | 3M | 3M |
| Retained Earnings | (998M) | (331M) | 443M | 1.01B | 1.11B |
| Accumulated OCI | (513M) | (564M) | (541M) | (649M) | (527M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (1.51B) | (892M) | (70M) | 472M | 752M |
| Total Debt | 9.36B | 9.11B | 8.93B | 9.04B | 8.8B |
| Net Debt | 8.63B | 8.41B | 8.24B | 8.36B | 8.23B |
Organon & Co.
NYSE:OGN
Intrinsic Alpha fair value
Locked
Current Price
$13.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.